Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016

Details for Mechanism ID: 18094
Country/Region: Democratic Republic of the Congo
Year: 2016
Main Partner: Pathfinder International
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $2,700,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $297,000
Care: TB/HIV (HVTB) $171,000
Care: Pediatric Care and Support (PDCS) $90,000
Laboratory Infrastructure (HLAB) $55,000
Strategic Information (HVSI) $29,000
Health Systems Strengthening (OHSS) $204,075
Biomedical Prevention: Injection Safety (HMIN) $59,000
Sexual Prevention: Abstinence/Be Faithful (HVAB) $15,000
Testing: HIV Testing and Counseling (HVCT) $400,000
Sexual Prevention: Other Sexual Prevention (HVOP) $69,925
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $168,000
Treatment: Adult Treatment (HTXS) $1,000,000
Treatment: Pediatric Treatment (PDTX) $142,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 9,110
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 6,104
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 111,649
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 40,878
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 167,741
HTS_TST Service Delivery Point (Facility): Index testing 2017 1,214
HTS_TST Service Delivery Point (Facility): Inpatient 2017 27,840
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 10,577
HTS_TST Service Delivery Point (Facility): Other PITC 2017 10,568
HTS_TST Service Delivery Point (Facility): Outpatient 2017 56,749
HTS_TST Service Delivery Point (Facility): Pediatric 2017 13,692
HTS_TST Service Delivery Point (Facility): PMTCT 2017 43,084
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,798
HTS_TST Service Delivery Point (Facility): VCT 2017 1,219
HTS_TST Sum of Aggregated Age/Sex <15 2017 15,214
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 152,527
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 167,741
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 321
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 218
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,799
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,574
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 165
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 165
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 165
PMTCT_ART Already on ART at beginning of current pregnancy 2017 134
PMTCT_ART New on ART 2017 675
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 43,477
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 529
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 240
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 3
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 4
PMTCT_EID Sum of Infant Age disaggregates 2017 769
PMTCT_STAT By: Known positives at entry 2017 226
PMTCT_STAT By: Number of new positives identified 2017 658
PMTCT_STAT Number of new ANC and L&D clients 2017 44,835
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 43,477
PMTCT_STAT Sum of Positives Status disaggregates 2017 884
PP_PREV Aggregated Age/sex: <15 Female 2017 70
PP_PREV Aggregated Age/sex: <15 Male 2017 88
PP_PREV Aggregated Age/sex: 15+ Female 2017 686
PP_PREV Aggregated Age/sex: 15+ Male 2017 931
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 1,775
PP_PREV Total number of people in the target population 2017 1,775
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 11
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 140
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 16
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 212
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 451
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 376
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,216
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 125
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 1,838
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 286
TB_SCREENDX Screen Result: Screened Positive for TB 2017 2,342
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 4,705
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 6,181
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 543
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 661
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 12,089
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 130
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,049
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 145
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,365
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 2,688
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 2,806
TX_CURR Aggregated Age/Sex: <15 Female 2017 2,168
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,455
TX_CURR Aggregated Age/Sex: 15+ Female 2017 16,420
TX_CURR Aggregated Age/Sex: 15+ Male 2017 5,232
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 25,280
TX_CURR Sum of Aggregated Age/Sex <15 2017 3,623
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 21,652
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 25,275
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 276
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 189
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 3,121
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,311
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 4,899
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 4,897
Cross Cutting Budget Categories and Known Amounts Total: $210,000
Motor Vehicles: Purchased $135,000
Gender: Gender Based Violence (GBV) $25,000
Post GBV Care
Implementation
Capacity building
Gender: Gender Equality $50,000
Changing harmful gender norms and promoting positive gender norms
Equity in HIV prevention, care, treatment and support